Metabolic pathways regulated by p63
- Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Rome (Italy)
- Medical Research Council, Toxicology Unit, Leicester LE1 9HN (United Kingdom)
- Department of Systems Medicine, University of Rome “Tor Vergata”, Rome (Italy)
- IDI-IRCCS “Istituto Dermopatico dell’Immacolata”, Biochemistry Laboratory, Rome (Italy)
The transcription factor p63 belongs to the p53-family and is a master regulator of proliferative potential, lineage specification, and differentiation in epithelia during development and tissue homeostasis. In cancer, p63 contribution is isoform-specific, with both oncogenic and tumour suppressive roles attributed, for ΔNp63 and TAp63, respectively. Recently, p53 and TAp73, in line with other tumour suppressor genes, have emerged as important regulators of energy metabolism and metabolic reprogramming in cancer. To date, p63 contributions in controlling energy metabolism have been partially investigated; given the extensive interaction of the p53 family members, these studies have potential implications in tumour cells for metabolic reprogramming. Here, we review the role of p63 isoforms, TAp63 and ΔNp63, in controlling cell metabolism, focusing on their specific metabolic target genes and their physiological/functional context of action. - Highlights: • The transcription factor p63 is involved in development and cancer. • p63 regulates glucose and lipid metabolism. • p63 contributes to anti-oxidant defences. • p63 regulates metabolism of cancer cells.
- OSTI ID:
- 22696761
- Journal Information:
- Biochemical and Biophysical Research Communications, Vol. 482, Issue 3; Other Information: Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Molecular Mechanisms of p63-Mediated Squamous Cancer Pathogenesis
Oncogenic Ras and ΔNp63α cooperate to recruit immunosuppressive polymorphonuclear myeloid-derived suppressor cells in a mouse model of squamous cancer pathogenesis